← Back to all trials
Recruiting
NCT07643012
Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer
Conditions: Endometrial Cancer
Sex: Female
Ages: 18 Years – 90 Years
Healthy volunteers: No
Phase: NA
Enrollment: 30
Sponsor: Rutgers, The State University of New Jersey
Location: Rutgers Cancer Institut Jersey New Brunswick New Jersey
Summary
To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.
Eligibility Criteria
Inclusion Criteria:
1. Histologically confirmed endometrial carcinoma (endometrioid, serous, clear cell, carcinosarcoma, or dedifferentiated histology).
2. Indication for adjuvant pelvic radiotherapy (± vaginal brachytherapy) for HIR defined by the ASTRO guidelines and GOG-99(7, 9) :
3. Age
4. High-grade histology (grade 2-3)
5. Depth of myometrial invasion
6. LVSI
7. Positive pelvic nodes
8. Cervical stromal invasion
9. Presence of poor prognostic molecular markers
10. Age ≥18 years.
11. Ability to provide informed consent.
12. Eligible to receive adjuvant systemic therapy, if indicated, with a minimum 3-week interval between chemotherapy and radiotherapy.
13. Willing and able to complete EORTC QLQ-C30 and EN-24 questionnaires in a validated language version.
Exclusion Criteria:
1. Prior pelvic radiotherapy.
2. Contraindication to pelvic radiotherapy (e.g., active connective tissue disorder or inflammatory bowel disease).
3. Presence of a hip prosthesis that would compromise treatment planning or delivery.
\-
Source: ClinicalTrials.gov (NCT07643012). StuddyBuddy aggregates publicly available trial information.
